Liquid Biopsy For Personalised Monitoring Of Melanoma Patients
Funder
National Health and Medical Research Council
Funding Amount
$820,888.00
Summary
Despite the success of recent melanoma treatments, therapies are effective long term in only a proportion of patients. Here we will progress preliminary findings in collaboration with biotechnology and pathology companies to develop highly effective companion biomarkers that will aid treatment decisions throughout disease course. Our team will spearhead translation of these markers into the clinic for routine monitoring of melanoma patients.
Unravelling The Mechanism Of MHC Class-I Associated Drug Hypersensitivities
Funder
National Health and Medical Research Council
Funding Amount
$566,308.00
Summary
Some drugs cause adverse reactions that are life threatening. We think these reactions are mediated by killer T cells as they are genetically controlled by immune response genes that normally guide immunity to microbes. We will study immune reactions to the drug abacavir, used to treat HIV (AIDS); allopurinol used to prevent gout and carbamazepine, used to treat epilepsy. The study may also help devise better treatments for patients who experience severe forms of these reactions.
Optimisation Of Antimicrobial Therapy For Severe Bacterial Infections In Neonates And Young Children In Papua New Guinea
Funder
National Health and Medical Research Council
Funding Amount
$943,865.00
Summary
This study aims to provide important information on the way young Papua New Guinean children with serious bacterial infections handle antibiotics, including newer agents that may be required if bacterial resistance is confirmed or increases. The data will be used to optimise treatment, thus reducing mortality and potential adverse drug effects, in PNG nad other tropical countries, and may have implications for the developed world as well.
Molecular Pharmacology Of Chemokine Receptor Signalling In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$371,770.00
Summary
Molecular pharmacology is the study of how hormones, neurotransmitters and pharmaceuticals interact with our cells through receptors, which transfer a signal across the cell membrane to change the function of that cell. Chemokine receptors are recognised to play a role in the development of many cancers. Understanding how these receptors work has enormous implications for improving our ability to develop better anti-cancer treatments with fewer side effects.
DYRK1A As A Novel Target For Glioblastoma Therapies
Funder
National Health and Medical Research Council
Funding Amount
$620,294.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.
Development of a prime-boost anti-cancer vaccine. New vaccination strategies are urgently needed for a variety of diseases, including cancer. The problem with cancer vaccines is that it is difficult to trigger a response to a self protein. We propose that a prime-boost vaccination, using yellow fever virus and modified vaccinia virus ankara, could create very strong responses against tumor antigens. This approach can be patented and can revive that field of tumor vaccination, which is currently ....Development of a prime-boost anti-cancer vaccine. New vaccination strategies are urgently needed for a variety of diseases, including cancer. The problem with cancer vaccines is that it is difficult to trigger a response to a self protein. We propose that a prime-boost vaccination, using yellow fever virus and modified vaccinia virus ankara, could create very strong responses against tumor antigens. This approach can be patented and can revive that field of tumor vaccination, which is currently restrained by the difficulty of breaking immunological tolerance. We envisage the construction of a anti-cancer vaccine vector with obvious market potential. An exciting prospect is that this approach could be used as a prophylactic vaccine and possibly also as a therapeutic vaccine.Read moreRead less
Establishing advanced networks for air quality sensing and analyses. Establishing advanced networks for air quality sensing and analyses. This project aims to develop innovative, cost-effective, high resolution air quality networks. Recent developments in sensor technologies improve the ability to harvest atmospheric data. This project will develop, validate and implement methods for high sensitivity atmospheric sensing and apply cutting-edge statistical and analytic techniques to the data sets, ....Establishing advanced networks for air quality sensing and analyses. Establishing advanced networks for air quality sensing and analyses. This project aims to develop innovative, cost-effective, high resolution air quality networks. Recent developments in sensor technologies improve the ability to harvest atmospheric data. This project will develop, validate and implement methods for high sensitivity atmospheric sensing and apply cutting-edge statistical and analytic techniques to the data sets, unprecedented in scope and resolution. Outcomes include an open access database to quantify and visualise intra-urban air pollution and human exposure and develop air quality maps and smoke pollution management tools. It is expected to advance the evidence-based management of air as a resource, increasing economic prosperity and enhancing human health and quality of life.Read moreRead less
Tracking formation-flying of nanosatellites using inter-satellite links. This project aims to realise real-time kinematic precise orbit and attitude determination of nano satellites. Formation flying, based on distributed miniaturised satellites such as Cubesats, is envisioned to revolutionise the way the space-science community conducts autonomous missions. The project will develop a purely kinematic concept exploiting the full capabilities of Global Navigation Satellite Systems (GNSS) carrier- ....Tracking formation-flying of nanosatellites using inter-satellite links. This project aims to realise real-time kinematic precise orbit and attitude determination of nano satellites. Formation flying, based on distributed miniaturised satellites such as Cubesats, is envisioned to revolutionise the way the space-science community conducts autonomous missions. The project will develop a purely kinematic concept exploiting the full capabilities of Global Navigation Satellite Systems (GNSS) carrier-phase measurements for instantaneous precise orbit and attitude determination of the Cubesats. The project will also pioneer the use of the satellite based augmentation systems (SBAS), supporting the future Australian SBAS program, and the development of integrated algorithms for space-based, Precise Point Positioning with fixed ambiguities supported by SBAS.Read moreRead less
Impact Of An Ivermectin Mass Drug Administration Program Against Endemic Scabies And Strongyloidiasis
Funder
National Health and Medical Research Council
Funding Amount
$1,289,786.00
Summary
Overseas studies suggest sustainable and long term benefits can be obtained through the use of ivermectin in mass drug administration programs to control parasitic infections. Our study will be a critical first step in establishing if such a program can be successful in a remote Indigenous community setting, where the disease burden from scabies and strongyloidiasis (threadworm infections) is very high.
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.